Rhythm Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$22.4M
Doctors Paid
2,199
Transactions
9,418
2024 Total
$8.0M
Payment Breakdown by Category
Research$21.6M (96.3%)
Food & Beverage$142,510 (0.6%)
Consulting$87,088 (0.4%)
Travel$72,980 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.6M | 4,980 | 96.3% |
| Honoraria | $503,401 | 366 | 2.2% |
| Food and Beverage | $142,510 | 3,742 | 0.6% |
| Consulting Fee | $87,088 | 54 | 0.4% |
| Travel and Lodging | $72,980 | 197 | 0.3% |
| Grant | $20,000 | 1 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,503 | 2 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,187 | 1 | 0.0% |
| Education | $3,173 | 75 | 0.0% |
Payments by Type
Research
$21.6M
4,980 transactions
General
$835,841
4,438 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Trial of Setmelanotide in Acquired Hypothalamic Obesity | $3.4M | 0 | 121 |
| RM-493-034 | $3.0M | 0 | 1,242 |
| EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | $2.5M | 0 | 1,394 |
| RM-493-035 | $2.4M | 0 | 894 |
| RM-493-014 | $2.3M | 0 | 188 |
| RM-493-022 | $2.0M | 0 | 191 |
| DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | $993,142 | 0 | 527 |
| RHYTH001_RM 493-040_80072978 | $768,484 | 0 | 42 |
| Long Term Extension Trial of Setmelanotide | $712,574 | 0 | 92 |
| RM-493-030 | $652,003 | 0 | 24 |
| RM-493-037/RM-493-022/RM-493-033 | $402,548 | 0 | 2 |
| RM-493-023 | $394,051 | 0 | 35 |
| RM-493-029 | $359,586 | 0 | 13 |
| RM-493-037/RM-493-022 | $245,882 | 0 | 1 |
| RM-493-014/RM-493-022 | $212,491 | 0 | 6 |
| RM-493-022/ RM-493-014 | $202,835 | 0 | 7 |
| RM-493-033 | $194,556 | 0 | 29 |
| RM-493-037 | $140,511 | 0 | 15 |
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | $140,328 | 0 | 25 |
| RM-493-037/RM-493-033/RM-493-022 | $122,313 | 0 | 2 |
| RM-493-013 | $91,949 | 0 | 35 |
| RM-493-033/RM-493-022 | $83,888 | 0 | 2 |
| Setmelanotide in Pediatric Patients With Rare Genetic Diseases of Obesity | $76,293 | 0 | 19 |
| RM-493-023/RM-493-014 | $30,897 | 0 | 1 |
| RM-493-030/RM-493-022 | $30,469 | 0 | 2 |
| Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Patients With Specific Gene Defects in the MC4R Pathway | $30,331 | 0 | 3 |
| RM-493-037/RM-493-033 | $27,606 | 0 | 3 |
| RM-493-033/RM-493-037 | $25,036 | 0 | 1 |
| RM-493-030/ RM-493-022 | $16,610 | 0 | 1 |
| RM-493-014/RM-493-022/RM-493-037 | $13,012 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Jennifer Paisley, Md, MD | Obesity Medicine | Lawrenceburg, IN | $54,124 | $0 |
| Dr. Gitanjali Srivastava, M.d, M.D | Internal Medicine | Nashville, TN | $42,118 | $0 |
| Vidhu Thaker, M.d, M.D | Pediatrics | New York, NY | $32,557 | $0 |
| Christy Davis, Fnp, FNP | Licensed Practical Nurse | Jackson, MS | $29,164 | $0 |
| Dr. Juliana Simonetti, M.d, M.D | Internal Medicine | Boston, MA | $28,755 | $0 |
| Svetlana Ten, Md, MD | Pediatric Endocrinology | Staten Island, NY | $25,391 | $0 |
| Dr. Suzanne Cuda, Md, MD | Adolescent Medicine | San Antonio, TX | $24,113 | $0 |
| Christian Roth, Md, MD | Pediatrics | Seattle, WA | $23,339 | $0 |
| Dr. Joshua Zaritsky, M.d, M.D | Nephrology | Phoenix, AZ | $22,859 | $0 |
| Dr. Heidi Shea, M.d, M.D | Endocrinology, Diabetes & Metabolism | Plano, TX | $22,379 | $0 |
| Dr. Shaista Safder, M.d, M.D | Pediatric Gastroenterology | Orlando, FL | $21,018 | $0 |
| Dr. Alaina Vidmar, M.d, M.D | Pediatric Endocrinology | Los Angeles, CA | $17,828 | $0 |
| Uzoma Okorie, Md, MD | Pediatric Cardiology | Marshfield, WI | $17,609 | $0 |
| Dr. Jose Gamez-Godoy, M.d, M.D | Pediatric Endocrinology | Edinburg, TX | $16,846 | $0 |
| Katie Queen, M.d, M.D | Pediatrics | Bogalusa, LA | $16,217 | $0 |
| Rushika Conroy, M.d, M.D | Pediatric Endocrinology | Portland, ME | $16,093 | $0 |
| Dr. Ashley Shoemaker, Md, MD | Pediatric Endocrinology | Nashville, TN | $15,543 | $0 |
| Dr. Natalio Izquierdo Encarnacion, Md, MD | Glaucoma Specialist | San Juan, PR | $15,188 | $0 |
| Jesse Richards, D.o, D.O | Internal Medicine | Tulsa, OK | $14,175 | $0 |
| Andrea Haqq, M.d, M.D | Endocrinology, Diabetes & Metabolism | Durham, NC | $13,064 | $0 |
| James Swain, M.d, M.D | Surgery | Scottsdale, AZ | $12,052 | $0 |
| Dr. Michael Dedekian, Md, MD | Pediatrics | Portland, ME | $11,932 | $0 |
| Jessica Duis, M.d, M.D | Clinical Genetics (M.D.) | Aurora, CO | $11,453 | $0 |
| Dr. Alessandro Iannaccone, Md, MD | Ophthalmology | Chapel Hill, NC | $10,896 | $0 |
| Dr. Ryan Morgan, D.o, D.O | Internal Medicine | Oklahoma City, OK | $10,540 | $0 |
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. has made $22.4M in payments to 2,199 healthcare providers, recorded across 9,418 transactions in the CMS Open Payments database. In 2024, the company paid $8.0M. The top product by payment volume is Imcivree ($14.1M).
Payments were distributed across 102 medical specialties. The top specialty by payment amount is Pediatric Endocrinology ($144,689 to 140 doctors).
Payment categories include: Food & Beverage ($142,510), Consulting ($87,088), Research ($21.6M), Travel & Lodging ($72,980).
Rhythm Pharmaceuticals, Inc. is associated with 3 products in the CMS Open Payments database.